The short version of provocative testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Physical side effects included pupil dilation, tingling, trembling, numbness, sweating, lightheadedness, athetosis, slight nausea, and increased heart rate and blood pressure. In addition to parenteral DMT, Shulgin described the effects of oral DMT plus harmaline or in some cases Peganum harmala seeds in TiHKAL. The effects were reported to include closed-eye imagery such as colors, infinitely repeated and wavy sheets of patterns, and kaleidoscopic images, visual changes like brighter colors and patterns and distortions, music enhancement, time distortion, clarity, insights, intoxication, emotional changes, feeling alive and excited, depression, despair, and feeling psychotic. Other effects included difficulty focusing on thoughts, short-term memory disruption, feeling cold, nausea, gait impairment or difficulty walking, and an afterglow. The preceding effects are variably due to both DMT and harmaline, with harmaline also producing its own hallucinogenic effects at sufficiently doses, for instance 150 mg or more.
Narrated by Julie Berry, produced by Jeremy Bugler, directed by Richard Klein, made by Fulmar Television & Film 4 September Walking on Water, about surfing, with Ken Bradshaw, Edward Coventry, Viscount Deerhurst; Waimea Bay has the largest ridable waves in the world, with 50 feet waves; the waves originate from Japan; Mark Foo, who later drowned that year at Mavericks, California; Huntington Beach, California, known as Surf City. Directed by Steve Stevenson, produced by Mike Wallington, made by Parvenu Productions 11 September The Cyborg Cometh, Austrian Manfred Clynes invented the term cyborg for NASA in the 1950s; Prof Donna Haraway, author of the 1985 A Cyborg Manifesto; the nascent internet, and SF Net; Mike Browne, who had a skiing accident in 1993 making him paraplegic, the founder of Snow and Rock, now owned by Cotswold Outdoor; Lisa Jean Moore, the semen industry, techno-semen, and The Sperm Bank of California; prenatal testing; David Bentley of the MRC's Human Genome Mapping Project at the Sanger Centre (now the Wellcome Sanger Institute).
== Awards == Major Awards 1. Young Scientist Medal (1988), by the Indian Science Congress Association, India. 2. INSA Young Scientist Medal (1991), by the Indian National Science Academy, New Delhi. 3. CRSI Bronze Medal (2002), by the Chemical Research Society of India. 4. MRSI Medal (2007), by Material Research Society of India. 5. Shanti Swarup Bhatnagar Prize (2007), awarded by CSIR, Govt. India. 6. DAE Outstanding Researcher Award (2009), awarded by Dept. Atomic Energy, Govt. India. 7. Thomson Reuters Research Excellence-India Research Front Award (2009). 8. The Infosys Prize for Physical Sciences 2012 by Infosys Science Foundation. 9. Khwarizmi International Award 2012 by Iranian Organisation for Science and Technology. 10. Swadeshi Innovation Award 2012 by the Swadeshi Science Movement, Kerala. 11. Sri Vidyadhiraja Samskrithi Puraskaram 2013 by Panmana Ashram, Quilon, Kerala. 12. CRSI Silver Medal 2013 by Chemical Research Society of India. 13. TWAS Chemistry Prize 2013 by The World Academy of Sciences, Trieste, Italy. 14. ISAS National Award for Excellence in Science and Technology 2014 by Indian Society of Analytical Scientists. 15. CHEMTECH CEW Award 2015 for Leadership and Excellence in Research and Development. 16. J. C. Bose National Fellowship, 2015, DST, Govt. India. 17. Web of Science-India Research Excellence-Citation Award 2017 by Clarivate Analytics. 18. MRSI Distinguished Lectureship Award, 2019-20, by Materials Research Society of India. 19. Goyal Prize for Chemical Science, 2019, by Kurukshetra University. Other Honors 1.
Beta blockers have a variety of drug interactions. An example is that various beta blockers including propranolol, carvedilol, nebivolol, timolol, and metoprolol are metabolized by the cytochrome P450 enzyme CYP2D6 and may be potentiated by CYP2D6 inhibitors like fluoxetine, paroxetine, duloxetine, and bupropion. This may increase the risk of adverse effects like bradycardia and hypotension.
Sources: en.wikipedia.org
Hemoglobin D – (α2βD2) – A variant form of hemoglobin. Hemoglobin H (β4) – A variant form of hemoglobin, formed by a tetramer of β chains, which may be present in variants of α thalassemia. Hemoglobin Barts (γ4) – A variant form of hemoglobin, formed by a tetramer of γ chains, which may be present in variants of α thalassemia. Hemoglobin S (α2βS2) – A variant form of hemoglobin found in people with sickle cell disease. There is a variation in the β-chain gene, causing a change in the properties of hemoglobin, which results in sickling of red blood cells. Hemoglobin C (α2βC2) – Another variant due to a variation in the β-chain gene. This variant causes a mild chronic hemolytic anemia. Hemoglobin E (α2βE2) – Another variant due to a variation in the β-chain gene. This variant causes a mild chronic hemolytic anemia. Hemoglobin AS – A heterozygous form causing sickle cell trait with one adult gene and one sickle cell disease gene Hemoglobin SC disease – A compound heterozygous form with one sickle gene and another encoding hemoglobin C. Hemoglobin Hopkins-2 – A variant form of hemoglobin that is sometimes viewed in combination with hemoglobin S to produce sickle cell disease.
The sale allows TGI Fridays to repay its $23.9 million bankruptcy loan, with about $8 million in cash left over. On January 29, 2025, it was announced TGI Fridays UK's flagship restaurant in Leicester Square, London, had closed down. On January 30, 2025, it was reported that 30 more locations had closed, which left the chain with only around 100 locations remaining in the US. On February 3, 2025, it was announced that 19 of TGI Fridays' corporate-owned restaurants had been sold to two separate franchisees: three to Sugarloaf Hospitality and 16 to Yadav Enterprises, and that TGI Fridays had rejected the leases for six more restaurants. On 31 October 2025, it was announced that Sugarloaf TGIF Management had acquired TGI Friday's 49 UK restaurants from Calveton UK and Breal Capital as part of an international consolidation of the brand under Ray Blanchette. Sugarloaf is establishing a UK-led management team for the restaurants. However, less than three months later, on 14 January 2026, TGI Fridays closed 16 restaurants and went into administration for the second time in a year.
Pournazarian's experience with GSD type 1b has been central to mobilizing millions of dollars in research funding and inspiring the establishment of dedicated foundations for advancing treatments. His family continues to be active in advocacy efforts, working with organizations such as CureGSD1b to support research and provide resources for affected families. (See inborn errors of carbohydrate metabolism for a full list of inherited diseases that affect glycogen synthesis, glycogen breakdown, or glucose breakdown.)
Sources: en.wikipedia.org
Focke-Wulf Flugzeugbau AG (German pronunciation: [ˌfɔkəˈvʊlf]) was a German manufacturer of civil and military aircraft before and during World War II. Many of the company's successful fighter aircraft designs were slight modifications of the Focke-Wulf Fw 190. It is one of the predecessor companies of today's Airbus.
White for hydrogen Black for carbon Blue for nitrogen Red for oxygen Deep yellow for sulfur Purple for phosphorus Light, medium, medium dark, and dark green for the halogens (F, Cl, Br, I) Silver for metals (Co, Fe, Ni, Cu)
Sleep apnea (sleep apnoea or sleep apnœa in British English) is a sleep-related breathing disorder in which repetitive pauses in breathing, periods of shallow breathing, or collapse of the upper airway during sleep result in poor ventilation and sleep disruption. Each pause in breathing can last for a few seconds to a few minutes and often occurs many times a night. A choking or snorting sound may occur when breathing resumes. Common symptoms include daytime sleepiness, snoring, and non-restorative sleep despite adequate duration of sleep. Because the disorder disrupts normal sleep, those affected may experience sleepiness or feel tired during the day. It is often a chronic condition. Sleep apnea may be categorized as obstructive sleep apnea (OSA), in which breathing is interrupted by a blockage of air flow, central sleep apnea (CSA), in which regular unconscious breath simply stops, or a combination of the two. OSA is the most common form. OSA has four key contributors; these include a narrow, crowded, or collapsible upper airway, an ineffective pharyngeal dilator muscle function during sleep, airway narrowing during sleep, and unstable control of breathing (high loop gain). In CSA, the basic neurological controls for breathing rate malfunction and fail to give the signal to inhale, causing the individual to miss one or more cycles of breathing. If the pause in breathing is long enough, the percentage of oxygen in the circulation can drop to a lower than normal level (hypoxemia) and the concentration of carbon dioxide can build to a higher than normal level (hypercapnia).
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.